Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Segal

Showing results (111-120 of 123) with videos related to

Pageof 13
Sort By:
Cell Death & Disease|April 26, 2019
BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survivalErinna F Lee, Tiffany J Harris, Sharon Tran, et al.
Blood|April 13, 2016
The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanismMary Ann Anderson, Jing Deng, John F Seymour, et al.
Cell Death and Differentiation|January 21, 2017
Combination of IAP antagonist and IFNγ activates novel caspase-10- and RIPK1-dependent cell death pathwaysMaria C Tanzer, Nufail Khan, James A Rickard, et al.
Cell Death and Differentiation|April 1, 2017
Anti-apoptotic proteins BCL-2, MCL-1 and A1 summate collectively to maintain survival of immune cell populations both in vitro and in vivoEmma M Carrington, Yifan Zhan, Jamie L Brady, et al.
ACS Medicinal Chemistry Letters|December 21, 2017
Design, Synthesis, and Biological Activity of 1,2,3-Triazolobenzodiazepine BET Bromodomain InhibitorsPhillip P Sharp, Jean-Marc Garnier, Tamas Hatfaludi, et al.
Blood|June 13, 2012
E6AP ubiquitin ligase regulates PML-induced senescence in Myc-driven lymphomagenesisKamil Wolyniec, Jake Shortt, Elisa de Stanchina, et al.
Science Translational Medicine|August 4, 2017
Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancerDelphine Merino, James R Whittle, François Vaillant, et al.
Leukemia|September 15, 2018
Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemiaDonia M Moujalled, Giovanna Pomilio, Corina Ghiurau, et al.
The American Journal of Sports Medicine|January 17, 2026
Comparison Between Performance of Disease-Specific and Region-Specific Patient-Reported Outcome Measures in Adolescents After Patellofemoral Stabilization Surgery: Data From the JUPITER CohortDavid Segal, Matthew W Veerkamp, Eric J Wall, et al.
Science (New York, N.Y.)|September 18, 2007
TLR3 deficiency in patients with herpes simplex encephalitisShen-Ying Zhang, Emmanuelle Jouanguy, Sophie Ugolini, et al.
Pageof 13

Showing results (111-120 of 123) with videos related to

Sort By:
Pageof 13
Cell Death & Disease|April 26, 2019
BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survivalErinna F Lee, Tiffany J Harris, Sharon Tran, et al.
Blood|April 13, 2016
The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanismMary Ann Anderson, Jing Deng, John F Seymour, et al.
Cell Death and Differentiation|January 21, 2017
Combination of IAP antagonist and IFNγ activates novel caspase-10- and RIPK1-dependent cell death pathwaysMaria C Tanzer, Nufail Khan, James A Rickard, et al.
Cell Death and Differentiation|April 1, 2017
Anti-apoptotic proteins BCL-2, MCL-1 and A1 summate collectively to maintain survival of immune cell populations both in vitro and in vivoEmma M Carrington, Yifan Zhan, Jamie L Brady, et al.
ACS Medicinal Chemistry Letters|December 21, 2017
Design, Synthesis, and Biological Activity of 1,2,3-Triazolobenzodiazepine BET Bromodomain InhibitorsPhillip P Sharp, Jean-Marc Garnier, Tamas Hatfaludi, et al.
Blood|June 13, 2012
E6AP ubiquitin ligase regulates PML-induced senescence in Myc-driven lymphomagenesisKamil Wolyniec, Jake Shortt, Elisa de Stanchina, et al.
Science Translational Medicine|August 4, 2017
Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancerDelphine Merino, James R Whittle, François Vaillant, et al.
Leukemia|September 15, 2018
Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemiaDonia M Moujalled, Giovanna Pomilio, Corina Ghiurau, et al.
The American Journal of Sports Medicine|January 17, 2026
Comparison Between Performance of Disease-Specific and Region-Specific Patient-Reported Outcome Measures in Adolescents After Patellofemoral Stabilization Surgery: Data From the JUPITER CohortDavid Segal, Matthew W Veerkamp, Eric J Wall, et al.
Science (New York, N.Y.)|September 18, 2007
TLR3 deficiency in patients with herpes simplex encephalitisShen-Ying Zhang, Emmanuelle Jouanguy, Sophie Ugolini, et al.
Pageof 13